Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Janssen R&D announced the initiation of the global Phase 3 CREDENCE study, which will examine whether Invokana (canagliflozin) can slow the progression of diabetic nephropathy in patients with type 2 diabetes. Invokana is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that blocks the reabsorption of glucose in the kidney, increases glucose excretion, and lowers blood glucose levels.
The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study is a randomized, double-blind, multicenter, placebo-controlled, parallel group trial designed to enroll more than 3,700 patients with type 2 diabetes and diabetic nephropathy. The trial will evaluate patients with type 2 diabetes and diabetic nephropathy receiving standard of care, which includes treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). The trial’s composite primary endpoint includes a doubling of serum creatinine, the occurrence of end-stage renal failure and cardiovascular death.
RELATED: Endocrine Disorders Resource Center
Invokana (Janssen Pharmaceuticals) is already approved as an adjunct to diet and exercise to lower blood sugar in adults with type 2 diabetes.
For more information call (800) 526-7736 or visit JanssenRnD.com.
